Enter symbol or company name here...
Ceapro Inc (CZO:CA)
*/?>
Web site:
http://www.ceapro.com/
Innovative and Profitable Biotech
Ceapro has always been active in the development of therapeutic natural active ingredients. This market has grown rapidly and will continue to grow as consumers continue to demand the personal care and cosmetic products they purchase are more natural and green. In 2010 Ceapro revenues exceeded $5.5 million dollars and operations were profitable. The first six months of 2011 has shown further growth in revenue and profitability. Ceapro is one of the very few Canadian biotech companies that generates revenue and profit and it has accomplished this through organic growth to date.
Human and Animal Health
Ceapro products are predominantly sold to the global personal care and cosmeceutical industries, targeting primarily dermatology applications. Dermatology applications include anti-inflammatory, anti-aging and would healing products. Ceapro products have recently been launched into the hair care market, with applications for colored hair retention and damaged hair. Ceapro has also developed a line of companion animal products utilizing its ingredients and these products are sold through veterinarians in Japan.
Ceapro ingredients are sold globally and can be found in several of the major multi-national brands that consumers buy everyday. This is a testament to the quality and efficacy of Ceapro products as they are required to undergo very rigorous testing before they are included in a global brand product.
Product Portfolio
Ceapro currently markets six different products to its customers.
- Avenanthramides, a potent anti-inflammatory uniquely found in oats.
- Oat beta glucan, the soluable fibre in oats that has demonstrated wrinkle reduction and would healing properties.
- Oat oil, containing high levels of anti-oxidants and natural emmolients
- Oat peptides, an excellent emulsifier with natural foaming properties
- Lupin peptides, superior color fast properties
- Colloidal oatmeal, manufactured to specific customer specifications, provide anti-irritant benefits
Ceapro products are protected by both patents and trade secrets.
Ceapro is recognized as a world leader in specialized oat products and has recently began producing and developing products from other botanicals. In addition to the lupin peptides currently marketed, Ceapro is advancing the commercialization of new products from unique varieties of spearmint and rosehips that will provide the opportunity to market new innovative products to the market.
Manufacturing
Ceapro manufactures its products utilizing a suite of manufacturing technologies that it has developed. These processes are protected by patents and trade secrets. The technologies utilized include:
- Green solvent extraction
- Aqueous extraction
- Supercritical extraction
- A novel drying technology is currently under development with scale up activities planned for Q3 2011.
Ceapro has experience in scaling up manufacturing to commercial status and most importantly the technologies have shown that they can produce good margins.
Untapped Potential
The demand for natural solutions for the personal care industry continues to grow and there continues to be several unmet needs that require new product solutions. Ceapro has identified that substantial growth can occur through:
- New customers for its existing products- as an example Ceapro products have on just entered the hair care market
- New indications for existing products- current research is finding new potential health indications for Ceapro products that were previously unknown
- New products- Ceapro has access to large customers with unmet needs who will be receptive to testing new products for commercial use
- Improved and novel manufacturing process- Ceapro is constantly reviewing processes to ensure profit margins remain strong
- New industries- new research conducted by Ceapro has shown promise that Ceapro ingredients could be used in the nutraceutical and pharmaceutical markets to provide health benefits.
CZO:CA
Category:
© 2008-2026